Results 161 to 170 of about 2,223,573 (201)

Correction to "The Underlying Mechanism Involved in Gefitinib Resistance and Corresponding Experiment Validation in Lung Cancer". [PDF]

Mediators Inflamm
europepmc   +1 more source

HIF-1α-HPRT1 axis promotes tumorigenesis and gefitinib resistance by enhancing purine metabolism in EGFR-mutant lung adenocarcinoma. [PDF]

J Exp Clin Cancer Res
Geng P, Ye F, Dou P, Hu C, He J, Zhao J, Li Q, Bao M, Li X, Liu X, Xu G.   +10 more
europepmc   +1 more source

FTO/m6A mediates miR-138-5p maturation and regulates gefitinib resistance of lung adenocarcinoma cells by miR-138-5p/LCN2 axis. [PDF]

BMC Cancer
Ding D, Shang W, Shi K, Ying J, Wang L, Chen Z, Zhang C.   +6 more
europepmc   +1 more source

Circ_0001786 facilitates gefitinib resistance and malignant progression in non-small cell lung cancer via miR-34b-5p/SRSF1. [PDF]

J Cardiothorac Surg
Ouyang K, Xie D, Liao H, He Y, Xiong H.
europepmc   +1 more source

Retraction Notice to: lncRNA UCA1 Promotes Gefitinib Resistance as a ceRNA to Target FOSL2 by Sponging miR-143 in Non-small Cell Lung Cancer. [PDF]

Mol Ther Nucleic Acids
Chen X, Wang Z, Tong F, Dong X, Wu G, Zhang R.   +5 more
europepmc   +1 more source

Correction: Circ_0001786 facilitates gefitinib resistance and malignant progression in non-small cell lung cancer via miR-34b-5p/SRSF1. [PDF]

J Cardiothorac Surg
Ouyang K, Xie D, Liao H, He Y, Xiong H.
europepmc   +1 more source

Statement of Retraction: The lncRNA RHPN1-AS1 downregulation promotes gefitinib resistance by targeting miR-299-3p/TNFSF12 pathway in NSCLC. [PDF]

Cell Cycle, 2022
europepmc   +1 more source

Prospective Assessment of Continuation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Pemetrexed [PDF]

Journal of Thoracic Oncology, 2013
Patients with epidermal growth factor receptor (EGFR) mutation positive non-small-cell lung cancer exhibited marked response to gefitinib or erlotinib. In most cases, however, the patients showed disease progression after EGFR-tyrosine kinase inhibitor (TKI) treatment.
Tomonori Hirashima, Shinzoh Kudoh
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Cancer exosomal microRNAs from gefitinib-resistant lung cancer cells cause therapeutic resistance in gefitinib-sensitive cells

Surgery Today, 2020
Exosomes and their cargo microRNAs play a significant role in various biological processes in cancer. We hypothesized that microRNAs in exosomes secreted by gefitinib-resistant lung cancer cells might induce resistant phenotypes in otherwise gefitinib-sensitive lung cancer cells.We isolated exosomes generated by the gefitinib-resistant human lung ...
Yoko, Azuma, Takehiko, Yokobori, Akira, Mogi, Toshiki, Yajima, Takayuki, Kosaka, Misaki, Iijima, Kimihiro, Shimizu, Ken, Shirabe, Hiroyuki, Kuwano   +8 more
openaire   +2 more sources

Resistance to gefitinib

International Journal of Clinical Oncology, 2006
Subsets of patients with non-small cell lung cancer (NSCLC) who carry somatic mutations in the epidermal growth factor receptor (EGFR) have responded remarkably well to a tyrosine kinase inhibitor (TKI), gefitinib. Despite the dramatic response to this inhibitor, most patients nevertheless ultimately have a relapse.
Hidetaka, Uramoto, Kenji, Sugio, Tsunehiro, Oyama, Masakazu, Sugaya, Takeshi, Hanagiri, Kosei, Yasumoto   +5 more
openaire   +2 more sources